Scholarlink

Background <p>Automated insulin delivery has been developed with various algorithms and designs. Omnipod 5 is the latest Commercially available device. We aimed to explore the safety efficacy and psychological impact of the new Omnipod hybrid closed-loop system.</p> Methods <p>We used PubMed, Google Scholar, Scopus, Web of Science, and Cochrane Library for our search, we analyzed pre and post-data for continuous glucose monitoring data and HbA1C using RevMan software. When we observed heterogeneity, we used random effect model otherwise fixed effect model was used. We addressed heterogeneity using leave-one-out sensitivity analysis. We performed subgroup analysis based on study design and age subgroups. We reported outcomes that couldn’t be analyzed narratively.</p> Results <p>Out of 12 studies with 13 reports, we analyzed pre and post-data of eight studies. Pooled data of 665 patients showed significant improvement in time in range 70-180mg/dl [MD 11.30% [95% CI: 9.75 to 12.84], P &lt; 0.00001]. Time above range 180mg/dl was significantly improved [MD -9.88% [95% CI: -11.52 to -8.25], P &lt; 0.00001]. Among six trials nighttime time below range 70mg/dl showed significant results TBR [MD -2.6% [95%CI: -3.77 to -1.44], p &lt; 0.0001] with Considerable heterogeneity that was fixed by sensitivity analysis. Omnpod hybrid closed loop [HCL] showed improvement in type 1 diabetes distress score which is consistent among reported studies.</p> Conclusion <p>Post Omnipod HCL usage showed improvement in 24h and nighttime which needs confirmation with more evidence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety, efficacy and psychological impact of Omnipod hybrid closed loop system in children, adolescents, and adults in 24 h and nighttime: Systematic review with additional meta-analysis

  • 期刊论文

  • 发表日期：

    2025年5月30日

查看全文
  • Rahma Mogahed Rateb,
  • Ismael Abdullah Kareem,
  • Ahlem Nour El yakine Bounechada,
  • Lyna Delhoum,
  • Fadi Qasim Altamimi,
  • Sara Aljawamis,
  • Aya Helmy Aboelyazid

摘要

Background

Automated insulin delivery has been developed with various algorithms and designs. Omnipod 5 is the latest Commercially available device. We aimed to explore the safety efficacy and psychological impact of the new Omnipod hybrid closed-loop system.

Methods

We used PubMed, Google Scholar, Scopus, Web of Science, and Cochrane Library for our search, we analyzed pre and post-data for continuous glucose monitoring data and HbA1C using RevMan software. When we observed heterogeneity, we used random effect model otherwise fixed effect model was used. We addressed heterogeneity using leave-one-out sensitivity analysis. We performed subgroup analysis based on study design and age subgroups. We reported outcomes that couldn’t be analyzed narratively.

Results

Out of 12 studies with 13 reports, we analyzed pre and post-data of eight studies. Pooled data of 665 patients showed significant improvement in time in range 70-180mg/dl [MD 11.30% [95% CI: 9.75 to 12.84], P < 0.00001]. Time above range 180mg/dl was significantly improved [MD -9.88% [95% CI: -11.52 to -8.25], P < 0.00001]. Among six trials nighttime time below range 70mg/dl showed significant results TBR [MD -2.6% [95%CI: -3.77 to -1.44], p < 0.0001] with Considerable heterogeneity that was fixed by sensitivity analysis. Omnpod hybrid closed loop [HCL] showed improvement in type 1 diabetes distress score which is consistent among reported studies.

Conclusion

Post Omnipod HCL usage showed improvement in 24h and nighttime which needs confirmation with more evidence.